View More
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA
Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com
Downloadable slideset reviewing the latest data on immunotherapy for patients with newly diagnosed advanced urothelial carcinoma, from Clinical Care Options (CCO)
Thomas Powles, MBBS, MRCP, MD
Released: September 21, 2020
Downloadable slideset on the latest data on treatment for patients with progressive urothelial carcinoma and insights on new horizons for immunotherapy in urothelial carcinoma, from Clinical Care Options (CCO)
Alain Ravaud, MD, PhD
Released: September 21, 2020
Commentary from Elizabeth R. Plimack, MD, MS on new treatment options, including erdafitinib and enfortumab vedotin, for urothelial cancer from CCO
Elizabeth R. Plimack, MD, MS
Released: September 15, 2020
From Clinical Care Options (CCO), expert commentary by Dr Richard Finn on the use of atezolizumab plus bevacizumab for advanced HCC
Richard Finn, MD
Released: September 15, 2020
You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.
CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.